{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T04:03:14Z","timestamp":1776484994410,"version":"3.51.2"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["T32DA024628-15"],"award-info":[{"award-number":["T32DA024628-15"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"name":"VA Health Services Research and Development (HSR&D) Center for Health Information and Communication","award":["CIN 13-416"],"award-info":[{"award-number":["CIN 13-416"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Longer duration of treatment with medication for opioid use disorder (MOUD) is associated with improved outcomes, but long-term retention remains a challenge. Research is needed to identify psychosocial interventions that support MOUD retention. To address this gap, we examined associations between a wide range of psychosocial services and buprenorphine treatment discontinuation across 18 months among a large cohort of Veterans initiating buprenorphine nationwide.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We identified a cohort of patients with new buprenorphine initiation in 2017\u20132018 in Veterans Health Administration electronic health record data (N =\u200911,704). We examined prescription fills for up to 18 months after initiation. The primary outcome was first discontinuation of buprenorphine. We examined a variety of services, including psychotherapy in specialty substance use disorder (SUD) and mental health clinics, other healthcare services, and residential programs. To examine time-varying associations between psychosocial services and risk of discontinuation, we fit extended Cox regression models for each service separately and simultaneously.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Overall, 80.5% of patients discontinued buprenorphine at least once within 18 months. Risk of discontinuation was 18% (HR: 0.82, 95% CI: 0.77, 0.87) relatively lower following SUD psychotherapy and 26% (HR: 1.26, 95% CI: 1.15,1.39) higher following residential treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Several services, including residential treatment, were associated with greater risk of subsequent buprenorphine discontinuation, whereas only SUD psychotherapy was consistently associated with lower risk of later discontinuation. These findings emphasize the need for future studies to increase understandings of beneficial and disruptive components of psychosocial services to improve treatment retention among patients receiving MOUD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13722-025-00562-1","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T11:11:47Z","timestamp":1744801907000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Buprenorphine discontinuation and utilization of psychosocial services: a national study in the Veterans Health Administration"],"prefix":"10.1186","volume":"20","author":[{"given":"Emma N.","family":"Cleary","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela L.","family":"Rollins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan B.","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura J.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick D.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"issue":"8","key":"562_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.27488","volume":"6","author":"CM Jones","year":"2023","unstructured":"Jones CM, Han B, Baldwin GT, Einstein EB, Compton WM. Use of medication for opioid use disorder among adults with past-year opioid use disorder in the US, 2021. JAMA Netw Open. 2023;6(8): e2327488. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.27488.","journal-title":"JAMA Netw Open"},{"key":"562_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109296","volume":"233","author":"MR Begley","year":"2022","unstructured":"Begley MR, Ravindran C, Peltzman T, Morley SW, Stephens BM, Ashrafioun L, McCarthy JF. Veteran drug overdose mortality, 2010\u20132019. Drug Alcohol Depend. 2022;233: 109296. https:\/\/doi.org\/10.1016\/j.drugalcdep.2022.109296.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"562_CR3","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1080\/07853890.2022.2092896","volume":"54","author":"AS Bennett","year":"2022","unstructured":"Bennett AS, Guarino H, Britton PC, O\u2019Brien-Mazza D, Cook SH, Taveras F, Cortez J, Elliott L. U.S. Military veterans and the opioid overdose crisis: a review of risk factors and prevention efforts. Ann Med. 2022;54(1):1826\u201338. https:\/\/doi.org\/10.1080\/07853890.2022.2092896.","journal-title":"Ann Med"},{"issue":"1","key":"562_CR4","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.amepre.2019.01.016","volume":"57","author":"LA Lin","year":"2019","unstructured":"Lin LA, Peltzman T, McCarthy JF, Oliva EM, Trafton JA, Bohnert ASB. Changing trends in opioid overdose deaths and prescription opioid receipt among veterans. Am J Prev Med. 2019;57(1):106\u201310. https:\/\/doi.org\/10.1016\/j.amepre.2019.01.016.","journal-title":"Am J Prev Med"},{"key":"562_CR5","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.addbeh.2018.12.007","volume":"92","author":"ML Kelley","year":"2019","unstructured":"Kelley ML, Bravo AJ, Votaw VR, Stein E, Redman JC, Witkiewitz K. Opioid and sedative misuse among veterans wounded in combat. Addict Behav. 2019;92:168\u201372. https:\/\/doi.org\/10.1016\/j.addbeh.2018.12.007.","journal-title":"Addict Behav"},{"key":"562_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.addbeh.2018.09.010","volume":"89","author":"S Meshberg-Cohen","year":"2019","unstructured":"Meshberg-Cohen S, Black AC, DeViva JC, Petrakis IL, Rosen MI. Trauma treatment for veterans in buprenorphine maintenance treatment for opioid use disorder. Addict Behav. 2019;89:29\u201334. https:\/\/doi.org\/10.1016\/j.addbeh.2018.09.010.","journal-title":"Addict Behav"},{"key":"562_CR7","doi-asserted-by":"crossref","unstructured":"Teeters JB, Lancaster CL, Brown DG, Back SE. Substance use disorders in military veterans: prevalence and treatment challenges. Substance Abuse Rehabil 2017:69\u201377.","DOI":"10.2147\/SAR.S116720"},{"issue":"2","key":"562_CR8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/08897077.2018.1452327","volume":"39","author":"JJ Wyse","year":"2018","unstructured":"Wyse JJ, Gordon AJ, Dobscha SK, Morasco BJ, Tiffany E, Drexler K, Sandbrink F, Lovejoy TI. Medications for opioid use disorder in the Department of Veterans Affairs (VA) health care system: historical perspective, lessons learned, and next steps. Substance Abuse. 2018;39(2):139\u201344. https:\/\/doi.org\/10.1080\/08897077.2018.1452327.","journal-title":"Substance Abuse"},{"issue":"2","key":"562_CR9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/HRP.0000000000000075","volume":"23","author":"HS Connery","year":"2015","unstructured":"Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry. 2015;23(2):63\u201375. https:\/\/doi.org\/10.1097\/HRP.0000000000000075.","journal-title":"Harv Rev Psychiatry"},{"issue":"3","key":"562_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.3821","volume":"5","author":"PM Mauro","year":"2022","unstructured":"Mauro PM, Gutkind S, Annunziato EM, Samples H. Use of medication for opioid use disorder among US adolescents and adults with need for opioid treatment, 2019. JAMA Netw Open. 2022;5(3): e223821. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.3821.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"562_CR11","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1001\/jamapsychiatry.2018.3126","volume":"76","author":"ND Volkow","year":"2019","unstructured":"Volkow ND, Jones EB, Einstein EB, Wargo EM. Prevention and treatment of opioid misuse and addiction: a review. JAMA Psychiat. 2019;76(2):208\u201316. https:\/\/doi.org\/10.1001\/jamapsychiatry.2018.3126.","journal-title":"JAMA Psychiat"},{"key":"562_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002207.pub4","author":"RP Mattick","year":"2014","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014. https:\/\/doi.org\/10.1002\/14651858.CD002207.pub4.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"562_CR13","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1176\/appi.ps.201300256","volume":"65","author":"CP Thomas","year":"2014","unstructured":"Thomas CP, Fullerton CA, Kim M, Montejano L, Lyman DR, Dougherty RH, Daniels AS, Ghose SS, Delphin-Rittmon ME. Medication-assisted treatment with buprenorphine: assessing the evidence. Psychiatr Serv. 2014;65(2):158\u201370. https:\/\/doi.org\/10.1176\/appi.ps.201300256.","journal-title":"Psychiatr Serv"},{"issue":"12","key":"562_CR14","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1038\/s41380-018-0094-5","volume":"24","author":"J Ma","year":"2019","unstructured":"Ma J, Bao YP, Wang RJ, Su MF, Liu MX, Li JQ, Degenhardt L, Farrell M, Blow FC, Ilgen M, Shi J, Lu L. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Mol Psychiatry. 2019;24(12):1868\u201383. https:\/\/doi.org\/10.1038\/s41380-018-0094-5.","journal-title":"Mol Psychiatry"},{"issue":"22","key":"562_CR15","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMp1402780","volume":"370","author":"ND Volkow","year":"2014","unstructured":"Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies\u2014tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063\u20136. https:\/\/doi.org\/10.1056\/NEJMp1402780.","journal-title":"N Engl J Med"},{"issue":"12","key":"562_CR16","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1001\/jamapsychiatry.2022.3118","volume":"79","author":"JB Gibbons","year":"2022","unstructured":"Gibbons JB, McCullough JS, Zivin K, Brown ZY, Norton EC. Association between buprenorphine treatment gaps, opioid overdose, and health care spending in us medicare beneficiaries with opioid use disorder. JAMA Psychiat. 2022;79(12):1173\u20139. https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.3118.","journal-title":"JAMA Psychiat"},{"issue":"12","key":"562_CR17","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1001\/jamainternmed.2014.5302","volume":"174","author":"DA Fiellin","year":"2014","unstructured":"Fiellin DA, Schottenfeld RS, Cutter CJ, Moore BA, Barry DT, O\u2019Connor PG. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Intern Med. 2014;174(12):1947\u201354. https:\/\/doi.org\/10.1001\/jamainternmed.2014.5302.","journal-title":"JAMA Intern Med"},{"issue":"5","key":"562_CR18","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/add.13270","volume":"111","author":"WH Lo-Ciganic","year":"2016","unstructured":"Lo-Ciganic WH, Gellad WF, Gordon AJ, Cochran G, Zemaitis MA, Cathers T, Kelley D, Donohue JM. Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization. Addiction. 2016;111(5):892\u2013902. https:\/\/doi.org\/10.1111\/add.13270.","journal-title":"Addiction"},{"key":"562_CR19","unstructured":"National Quality Forum. National Quality Forum (NQF); Behavioral health 2016\u20132017: Technical report; Department of Health and Human Services (2017). https:\/\/www.qualityforum.org\/Publications\/2017\/08\/Behavioral_Health_2016-2017_Final_Report.aspx."},{"key":"562_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jsat.2018.09.001","volume":"95","author":"H Samples","year":"2018","unstructured":"Samples H, Williams AR, Olfson M, Crystal S. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees. J Subst Abuse Treat. 2018;95:9\u201317. https:\/\/doi.org\/10.1016\/j.jsat.2018.09.001.","journal-title":"J Subst Abuse Treat"},{"issue":"5","key":"562_CR21","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1176\/appi.ajp.20230808","volume":"181","author":"AR Williams","year":"2024","unstructured":"Williams AR, Mauro CM, Huber B, Chiodo L, Crystal S, Samples H, Olfson M. Defining discontinuation for buprenorphine treatment: implications for quality measurement. Am J Psychiatry. 2024;181(5):457\u20139. https:\/\/doi.org\/10.1176\/appi.ajp.20230808.","journal-title":"Am J Psychiatry"},{"issue":"8","key":"562_CR22","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1176\/appi.ajp.2016.16070792","volume":"174","author":"KM Carroll","year":"2017","unstructured":"Carroll KM, Weiss RD. The role of behavioral interventions in buprenorphine maintenance treatment: a review. Am J Psychiatry. 2017;174(8):738\u201347. https:\/\/doi.org\/10.1176\/appi.ajp.2016.16070792.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"562_CR23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/m17-3107","volume":"169","author":"MR Larochelle","year":"2018","unstructured":"Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, Bagley SM, Liebschutz JM, Walley AY. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169(3):137\u201345. https:\/\/doi.org\/10.7326\/m17-3107.","journal-title":"Ann Intern Med"},{"key":"562_CR24","doi-asserted-by":"publisher","first-page":"109902","DOI":"10.1016\/j.drugalcdep.2023.109902","volume":"248","author":"AJ Gordon","year":"2023","unstructured":"Gordon AJ, Saxon AJ, Kertesz S, Wyse JJ, Manhapra A, Lin LA, Chen W, Hansen J, Pinnell D, Huynh T. Buprenorphine use and courses of care for opioid use disorder treatment within the Veterans Health Administration. Drug Alcohol Depend. 2023;248:109902. https:\/\/doi.org\/10.1016\/j.drugalcdep.2023.109902.","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"562_CR25","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/ajad.12553","volume":"26","author":"A Manhapra","year":"2017","unstructured":"Manhapra A, Petrakis I, Rosenheck R. Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration. Am J Addict. 2017;26(6):572\u201380. https:\/\/doi.org\/10.1111\/ajad.12553.","journal-title":"Am J Addict"},{"issue":"2","key":"562_CR26","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/1475-6773.13919","volume":"57","author":"JP Vakkalanka","year":"2022","unstructured":"Vakkalanka JP, Lund BC, Arndt S, Field W, Charlton M, Ward MM, Carnahan RM. Therapeutic relationships between Veterans and buprenorphine providers and effects on treatment retention. Health Serv Res. 2022;57(2):392\u2013402. https:\/\/doi.org\/10.1111\/1475-6773.13919.","journal-title":"Health Serv Res"},{"issue":"7","key":"562_CR27","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1007\/s11606-021-06969-1","volume":"37","author":"JP Vakkalanka","year":"2022","unstructured":"Vakkalanka JP, Lund BC, Ward MM, Arndt S, Field RW, Charlton M, Carnahan RM. Telehealth utilization is associated with lower risk of discontinuation of buprenorphine: a retrospective cohort study of US veterans. J Gen Intern Med. 2022;37(7):1610\u20138. https:\/\/doi.org\/10.1007\/s11606-021-06969-1.","journal-title":"J Gen Intern Med"},{"issue":"12","key":"562_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0244401","volume":"15","author":"D Rice","year":"2020","unstructured":"Rice D, Corace K, Wolfe D, Esmaeilisaraji L, Michaud A, Grima A, Austin B, Douma R, Barbeau P, Butler C, Willows M, Poulin PA, Sproule BA, Porath A, Garber G, Taha S, Garner G, Skidmore B, Moher D, Thavorn K, Hutton B. Evaluating comparative effectiveness of psychosocial interventions adjunctive to opioid agonist therapy for opioid use disorder: A systematic review with network meta-analyses. PLoS ONE. 2020;15(12): e0244401. https:\/\/doi.org\/10.1371\/journal.pone.0244401.","journal-title":"PLoS ONE"},{"key":"562_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2022.108774","volume":"139","author":"H Samples","year":"2022","unstructured":"Samples H, Williams AR, Crystal S, Olfson M. Psychosocial and behavioral therapy in conjunction with medication for opioid use disorder: Patterns, predictors, and association with buprenorphine treatment outcomes. J Subst Abuse Treat. 2022;139: 108774. https:\/\/doi.org\/10.1016\/j.jsat.2022.108774.","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"562_CR30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","volume":"35","author":"C Timko","year":"2016","unstructured":"Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Disord. 2016;35(1):22\u201335. https:\/\/doi.org\/10.1080\/10550887.2016.1100960.","journal-title":"J Addict Disord"},{"key":"562_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108923","volume":"228","author":"JJ Wyse","year":"2021","unstructured":"Wyse JJ, Morasco BJ, Dougherty J, Edwards B, Kansagara D, Gordon AJ, Korthuis PT, Tuepker A, Lindner S, Mackey K. Adjunct interventions to standard medical management of buprenorphine in outpatient settings: a systematic review of the evidence. Drug Alcohol Depend. 2021;228: 108923. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.108923.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"562_CR32","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1080\/10852352.2021.1934940","volume":"50","author":"LA Jason","year":"2022","unstructured":"Jason LA, Majer JM, Bobak TJ, O\u2019Brien J. Medication assisted therapy and recovery homes. J Prev Interv Community. 2022;50(2):178\u201390. https:\/\/doi.org\/10.1080\/10852352.2021.1934940.","journal-title":"J Prev Interv Community"},{"key":"562_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2022.108747","volume":"138","author":"CA Wood","year":"2022","unstructured":"Wood CA, Duello A, Miles J, Lohmann B, Gochez-Kerr T, Richardson K, Anderson-Harper R, Winograd RP. Acceptance of medications for opioid use disorder in recovery housing programs in Missouri. J Subst Abuse Treat. 2022;138: 108747. https:\/\/doi.org\/10.1016\/j.jsat.2022.108747.","journal-title":"J Subst Abuse Treat"},{"issue":"10118","key":"562_CR34","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","volume":"391","author":"JD Lee","year":"2018","unstructured":"Lee JD, Nunes EV Jr, Novo P, Bachrach K, Bailey GL, Bhatt S, Farkas S, Fishman M, Gauthier P, Hodgkins CC, King J, Lindblad R, Liu D, Matthews AG, May J, Peavy KM, Ross S, Salazar D, Schkolnik P, Shmueli-Blumberg D, Stablein D, Subramaniam G, Rotrosen J. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309\u201318. https:\/\/doi.org\/10.1016\/S0140-6736(17)32812-X.","journal-title":"Lancet"},{"issue":"1","key":"562_CR35","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.mcna.2021.09.001","volume":"106","author":"T Hickey","year":"2022","unstructured":"Hickey T, Abelleira A, Acampora G, Becker WC, Falker CG, Nazario M, Weimer MB. Perioperative buprenorphine management: a multidisciplinary approach. Medical Clinics. 2022;106(1):169\u201385. https:\/\/doi.org\/10.1016\/j.mcna.2021.09.001.","journal-title":"Medical Clinics"},{"issue":"10","key":"562_CR36","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.36298","volume":"5","author":"MC Frost","year":"2022","unstructured":"Frost MC, Zhang L, Kim HM, Lin LA. Use of and retention on video, telephone, and in-person buprenorphine treatment for opioid use disorder during the COVID-19 pandemic. JAMA Netw Open. 2022;5(10): e2236298. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.36298.","journal-title":"JAMA Netw Open"},{"key":"562_CR37","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jsat.2017.07.001","volume":"85","author":"JR Morgan","year":"2018","unstructured":"Morgan JR, Schackman BR, Leff JA, Linas BP, Walley AY. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. J Subst Abuse Treat. 2018;85:90\u20136. https:\/\/doi.org\/10.1016\/j.jsat.2017.07.001.","journal-title":"J Subst Abuse Treat"},{"issue":"7","key":"562_CR38","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1176\/appi.ps.201700363","volume":"69","author":"A Manhapra","year":"2018","unstructured":"Manhapra A, Agbese E, Leslie DL, Rosenheck RA. Three-year retention in buprenorphine treatment for opioid use disorder among privately insured adults. Psychiatr Serv. 2018;69(7):768\u201376. https:\/\/doi.org\/10.1176\/appi.ps.201700363.","journal-title":"Psychiatr Serv"},{"issue":"3","key":"562_CR39","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/wps.20784","volume":"19","author":"GR Bond","year":"2020","unstructured":"Bond GR, Drake RE, Becker DR. An update on individual placement and support. World Psychiatry. 2020;19(3):390. https:\/\/doi.org\/10.1002\/wps.20784.","journal-title":"World Psychiatry"},{"issue":"2","key":"562_CR40","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1177\/0887403414562601","volume":"27","author":"AK Finlay","year":"2016","unstructured":"Finlay AK, Smelson D, Sawh L, McGuire J, Rosenthal J, Blue-Howells J, Timko C, Binswanger I, Frayne SM, Blodgett JC. US Department of Veterans Affairs Veterans Justice Outreach program: Connecting justice-involved veterans with mental health and substance use disorder treatment. Crim Justice Policy Rev. 2016;27(2):203\u201322. https:\/\/doi.org\/10.1177\/0887403414562601.","journal-title":"Crim Justice Policy Rev"},{"key":"562_CR41","unstructured":"Gonsoulin M. Using SQL to \u201cSort Out\u201d Race in CDW: A method for cleaning multiple values of race. (Vol. no.6). VA Information Resource Center. RNB6-CDW-SQL-to-Sort-Out-Race-CY16.pdf (va.gov). 2016."},{"issue":"5","key":"562_CR42","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/ADM.0000000000000045","volume":"8","author":"MR Lofwall","year":"2014","unstructured":"Lofwall MR, Walsh SL. A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. J Addict Med. 2014;8(5):315\u201326. https:\/\/doi.org\/10.1097\/ADM.0000000000000045.","journal-title":"J Addict Med"},{"issue":"3","key":"562_CR43","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/aje\/kwn135","volume":"168","author":"S Suissa","year":"2008","unstructured":"Suissa S. Immeasurable time bias in observational studies of drug effects on mortality. Am J Epidemiol. 2008;168(3):329\u201335. https:\/\/doi.org\/10.1093\/aje\/kwn135.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"562_CR44","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3122\/jabfm.2022.01.210292","volume":"35","author":"AG Mirer","year":"2022","unstructured":"Mirer AG, Tiemstra JD, Hammes NE, Cloum HM, LaFavor KJ. Integrating buprenorphine treatment for opioid use with primary care is associated with greater retention in treatment. J Am Board Fam Med. 2022;35(1):206\u20138. https:\/\/doi.org\/10.3122\/jabfm.2022.01.210292.","journal-title":"J Am Board Fam Med"},{"key":"562_CR45","doi-asserted-by":"publisher","DOI":"10.1111\/add.16659","author":"CJ Hayes","year":"2024","unstructured":"Hayes CJ, Raciborski RA, Nowak M, Acharya M, Nunes EV Jr, Winhusen TJ. Medications for opioid use disorder: predictors of early discontinuation and reduction of overdose risk in US military veterans by medication type. Addiction. 2024. https:\/\/doi.org\/10.1111\/add.16659.","journal-title":"Addiction"},{"issue":"17","key":"562_CR46","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1001\/jama.2016.16435","volume":"316","author":"DN Kyriacou","year":"2016","unstructured":"Kyriacou DN, Lewis RJ. Confounding by indication in clinical research. JAMA. 2016;316(17):1818\u20139. https:\/\/doi.org\/10.1001\/jama.2016.16435.","journal-title":"JAMA"},{"key":"562_CR47","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.drugalcdep.2017.12.020","volume":"185","author":"D DePhilippis","year":"2018","unstructured":"DePhilippis D, Petry NM, Bonn-Miller MO, Rosenbach SB, McKay JR. The national implementation of Contingency Management (CM) in the Department of Veterans Affairs: attendance at CM sessions and substance use outcomes. Drug Alcohol Depend. 2018;185:367\u201373. https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.12.020.","journal-title":"Drug Alcohol Depend"},{"key":"562_CR48","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.addbeh.2019.01.020","volume":"93","author":"C Truong","year":"2019","unstructured":"Truong C, Krawczyk N, Dejman M, Marshall-Shah S, Tormohlen K, Agus D, Bass J. Challenges on the road to recovery: exploring attitudes and experiences of clients in a community-based buprenorphine program in Baltimore City. Addict Behav. 2019;93:14\u20139. https:\/\/doi.org\/10.1016\/j.addbeh.2019.01.020.","journal-title":"Addict Behav"},{"issue":"6","key":"562_CR49","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/ADM.0000000000000789","volume":"15","author":"JE Zweben","year":"2021","unstructured":"Zweben JE, Sorensen JL, Shingle M, Blazes CK. Discontinuing methadone and buprenorphine: a review and clinical challenges. J Addict Med. 2021;15(6):454\u201360. https:\/\/doi.org\/10.1097\/ADM.0000000000000789.","journal-title":"J Addict Med"},{"issue":"2","key":"562_CR50","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1037\/a0022776","volume":"25","author":"AJ Gordon","year":"2011","unstructured":"Gordon AJ, Kavanagh G, Krumm M, Ramgopal R, Paidisetty S, Aghevli M, Goodman F, Trafton J, Liberto J. Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration. Psychol Addict Behav. 2011;25(2):215\u201324. https:\/\/doi.org\/10.1037\/a0022776.","journal-title":"Psychol Addict Behav"},{"issue":"1","key":"562_CR51","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13722-022-00318-1","volume":"17","author":"DM Hartung","year":"2022","unstructured":"Hartung DM, Markwardt S, Johnston K, Geddes J, Baker R, Leichtling G, Hildebran C, Chan B, Cook RR, McCarty D, Ghitza U, Korthuis PT. Association between treatment setting and outcomes among oregon medicaid patients with opioid use disorder: a retrospective cohort study. Addict Sci Clin Pract. 2022;17(1):45. https:\/\/doi.org\/10.1186\/s13722-022-00318-1.","journal-title":"Addict Sci Clin Pract"},{"key":"562_CR52","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jsat.2016.12.010","volume":"74","author":"ZM Weinstein","year":"2017","unstructured":"Weinstein ZM, Kim HW, Cheng DM, Quinn E, Hui D, Labelle CT, Drainoni ML, Bachman SS, Samet JH. Long-term retention in Office Based Opioid Treatment with buprenorphine. J Subst Abuse Treat. 2017;74:65\u201370. https:\/\/doi.org\/10.1016\/j.jsat.2016.12.010.","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"562_CR53","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/ADM.0000000000000719","volume":"15","author":"AK Finlay","year":"2021","unstructured":"Finlay AK, Harris AH, Timko C, Yu M, Smelson D, Stimmel M, Binswanger IA. Disparities in access to medications for opioid use disorder in the Veterans Health Administration. J Addict Med. 2021;15(2):143.","journal-title":"J Addict Med"},{"issue":"9","key":"562_CR54","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2019.0876","volume":"76","author":"PA Lagisetty","year":"2019","unstructured":"Lagisetty PA, Ross R, Bohnert A, Clay M, Maust DT. Buprenorphine treatment divide by race\/ethnicity and payment. JAMA Psychiat. 2019;76(9):979\u201381. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.0876.","journal-title":"JAMA Psychiat"},{"issue":"1","key":"562_CR55","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1080\/08897077.2022.2060424","volume":"43","author":"RK Landis","year":"2022","unstructured":"Landis RK, Levin JS, Saloner B, Gordon AJ, Dick AW, Sherry TB, Leslie DL, Sorbero M, Stein BD. Sociodemographic differences in quality of treatment to Medicaid enrollees receiving buprenorphine. Subst Abus. 2022;43(1):1057\u201371. https:\/\/doi.org\/10.1080\/08897077.2022.2060424.","journal-title":"Subst Abus"},{"issue":"9","key":"562_CR56","doi-asserted-by":"publisher","first-page":"e2334540","DOI":"10.1001\/jamanetworkopen.2023.34540","volume":"6","author":"LC Chambers","year":"2023","unstructured":"Chambers LC, Hallowell BD, Zullo AR, Paiva TJ, Berk J, Gaither R, Hampson AJ, Beaudoin FL, Wightman RS. Buprenorphine dose and time to discontinuation among patients with opioid use disorder in the era of fentanyl. JAMA Netw Open. 2023;6(9):e2334540. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.34540.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"562_CR57","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/epirev\/mxaa001","volume":"42","author":"A Viera","year":"2020","unstructured":"Viera A, Bromberg DJ, Whittaker S, Refsland BM, Stanojlovic M, Nyhan K, Altice FL. Adherence to and retention in medications for opioid use disorder among adolescents and young adults. Epidemiol Rev. 2020;42(1):41\u201356. https:\/\/doi.org\/10.1093\/epirev\/mxaa001.","journal-title":"Epidemiol Rev"},{"issue":"1","key":"562_CR58","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jadohealth.2022.08.026","volume":"72","author":"SM Bagley","year":"2023","unstructured":"Bagley SM, Schoenberger SF, et al. Ambivalence and stigma beliefs about medication treatment among young adults with opioid use disorder: a qualitative exploration of young adults\u2019 perspectives. J Adolesc Health. 2023;72(1):105\u201310. https:\/\/doi.org\/10.1016\/j.jadohealth.2022.08.026.","journal-title":"J Adolesc Health"},{"key":"562_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2022.108918","volume":"144","author":"JM Husain","year":"2023","unstructured":"Husain JM, Cromartie D, Fitzelle-Jones E, Brochier A, Borba CP, Montalvo C. A qualitative analysis of barriers to opioid agonist treatment for racial\/ethnic minoritized populations. J Subst Abuse Treat. 2023;144: 108918. https:\/\/doi.org\/10.1016\/j.jsat.2022.108918.","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"562_CR60","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1177\/1073110518782949","volume":"46","author":"K James","year":"2021","unstructured":"James K, Jordan A. The opioid crisis in black communities. J Law Med Ethics. 2021;46(2):404\u201321. https:\/\/doi.org\/10.1177\/1073110518782949.","journal-title":"J Law Med Ethics"},{"issue":"1","key":"562_CR61","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13722-020-00199-2","volume":"15","author":"KC Osilla","year":"2020","unstructured":"Osilla KC, Becker K, Ecola L, Hurley B, Manuel JK, Ober A, Paddock SM, Watkins KE. Study design to evaluate a group-based therapy for support persons of adults on buprenorphine\/naloxone. Addict Sci Clin Pract. 2020;15(1):25. https:\/\/doi.org\/10.1186\/s13722-020-00199-2.","journal-title":"Addict Sci Clin Pract"},{"issue":"3","key":"562_CR62","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jsat.2013.10.004","volume":"46","author":"J Gryczynski","year":"2014","unstructured":"Gryczynski J, Mitchell SG, Jaffe JH, O\u2019Grady KE, Olsen YK, Schwartz RP. Leaving buprenorphine treatment: patients\u2019 reasons for cessation of care. J Subst Abuse Treat. 2014;46(3):356\u201361. https:\/\/doi.org\/10.1016\/j.jsat.2013.10.004.","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"562_CR63","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/ADM.0000000000001292","volume":"18","author":"JJ Wyse","year":"2024","unstructured":"Wyse JJ, Eckhardt A, Waller D, Gordon AJ, Shull S, Lovejoy TI, Mackey K, Morasco BJ. Patients\u2019 perspectives on discontinuing buprenorphine for the treatment of opioid use disorder. J Addict Med. 2024;18(3):300\u20135. https:\/\/doi.org\/10.1097\/ADM.0000000000001292.","journal-title":"J Addict Med"},{"issue":"1\u20132","key":"562_CR64","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.drugalcdep.2012.12.010","volume":"131","author":"JA Dreifuss","year":"2013","unstructured":"Dreifuss JA, Griffin ML, Frost K, Fitzmaurice GM, Potter JS, Fiellin DA, Selzer J, Hatch-Maillette M, Sonne SC, Weiss RD. Patient characteristics associated with buprenorphine\/naloxone treatment outcome for prescription opioid dependence: results from a multisite study. Drug Alcohol Depend. 2013;131(1\u20132):112\u20138. https:\/\/doi.org\/10.1016\/j.drugalcdep.2012.12.010.","journal-title":"Drug Alcohol Depend"},{"key":"562_CR65","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.drugalcdep.2017.05.049","volume":"179","author":"P Alves","year":"2017","unstructured":"Alves P, Sales C, Ashworth M. Does outcome measurement of treatment for substance use disorder reflect the personal concerns of patients? A scoping review of measures recommended in Europe. Drug Alcohol Depend. 2017;179:299\u2013308. https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.05.049.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"562_CR66","doi-asserted-by":"publisher","first-page":"26992","DOI":"10.4088\/pcc.18m02350","volume":"21","author":"BN Meffert","year":"2019","unstructured":"Meffert BN, Morabito DM, Sawicki DA, Hausman C, Southwick SM, Pietrzak RH, Heinz AJ. US veterans who do and do not utilize Veterans Affairs health care services: demographic, military, medical, and psychosocial characteristics. Prim Care Compan CNS Disord. 2019;21(1):26992. https:\/\/doi.org\/10.4088\/pcc.18m02350.","journal-title":"Prim Care Compan CNS Disord"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00562-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-025-00562-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00562-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T11:11:50Z","timestamp":1744801910000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-025-00562-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["562"],"URL":"https:\/\/doi.org\/10.1186\/s13722-025-00562-1","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"16 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All human subjects procedures in this study were approved by the Indiana University Institutional Review Board, as well the VA Research and Development Committee of the Richard L. Roudebush VA Medical Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}